Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (494,000)	$ (1,544,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	256,000	801,000
Common stock issued for services	207,000	17,000
Interest expense related to amortization of the discount on note payable	3,000	4,000
Fair value of warrant issued for interest	30,000	0
PPP loan forgiveness	0	(174,000)
Loss on investment in South Korean joint venture	6,000	8,000
Depreciation expense	22,000	2,000
Changes in assets and liabilities:
Accounts receivable	(316,000)	(178,000)
Inventories	(17,000)	(29,000)
Prepaid expenses and other assets	25,000	(59,000)
Deferred revenue	4,000	(89,000)
Right of use and lease liability, net	4,000	0
Deposit	(71,000)	12,000
Net cash used in operating activities	(43,000)	(1,140,000)
Cash flows from investing activities
Equipment purchases	(48,000)	(32,000)
Net cash used in investing activities	(48,000)	(32,000)
Cash flows from financing activities
Proceeds from sale of common stock	800,000	1,202,000
Repayment of note payable	(50,000)	0
Repayment by Clyra on inventory line of credit	(15,000)	(10,000)
Proceeds from sale of Clyra Medical preferred stock	225,000	0
Net cash provided by financing activities	1,510,000	1,192,000
Net effect of foreign currency translation	(6,000)	(8,000)
Net change in cash	1,413,000	12,000
Cash at beginning of year	1,851,000	962,000
Cash at end of period	3,264,000	974,000
Supplemental disclosures of cash flow information
Interest	15,000	7,000
Income taxes	5,000	0
Short-term lease payments not included in lease liability	13,000	52,000
Non-cash investing and financing activities
Equipment added via vehicle loan	80,000	0
Allocation of noncontrolling interest	467,000	528,000
Conversion of Clyra Common Stock to BioLargo Common Stock [Member]
Non-cash investing and financing activities
Conversion of Clyra common stock to BioLargo common stock	100,000	0
Conversion of Intercompany Receivable into Clyra Shares [Member]
Non-cash investing and financing activities
Conversion of intercompany receivable into Clyra shares	0	633,000
BETI Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	550,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	284,000	114,000
Accounts payable and accrued expenses	284,000	114,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	14,000	(25,000)
Accounts payable and accrued expenses	$ 14,000	$ (25,000)